https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-27 / J. Virol. 2017 08;91(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-27 / J. Virol. 2017 08;91(16)2017-07-27 00:00:002017-07-27 00:00:00Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells : Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-15 / Cancer Immunol. Immunother. 2017 Oct;66(10):1249-1264
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-15 / Cancer Immunol. Immunother. 2017 Oct;66(10):1249-12642017-07-15 00:00:002019-02-15 09:23:07Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-2713
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-27132017-06-03 00:00:002019-02-15 08:39:31Evaluation of the oncolytic potential of RB Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-849
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-8492017-06-01 00:00:002017-06-01 00:00:00Oncolytic Viruses in Cancer Treatment: A Review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-477
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-4772017-06-01 00:00:002017-06-01 00:00:00Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-23 / Cancer Res. 2017 08;77(15):4146-4157
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-23 / Cancer Res. 2017 08;77(15):4146-41572017-05-23 00:00:002019-02-15 09:23:10Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-20 / Int J Mol Sci 2017 May;18(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-20 / Int J Mol Sci 2017 May;18(5)2017-05-20 00:00:002021-11-15 16:51:51Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-15 / Front Immunol 2017;8:555
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-15 / Front Immunol 2017;8:5552017-05-15 00:00:002019-02-15 09:23:11Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-4742017-03-05 00:00:002019-02-15 08:47:44Immune and viral therapies for malignant primary brain tumors
